Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisBiologic interventions for fatigue in rheumatoid arthritisTargeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseaseMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsEffect and treatment of chronic pain in inflammatory arthritisHealth-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsComparing Five Year Out-Come in Two Cohorts of Patients with Early Rheumatoid Arthritis - A BARFOT Study.Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerationsInflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.The influence of long distance running on sonographic joint and tendon pathology: results from a prospective study with marathon runners.Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs.Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan.New anti-inflammatory targets for chronic obstructive pulmonary disease.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.Inflammation and the Silent Sequelae of Stroke.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab.Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
P2860
Q24185797-4EAAE736-979E-4F18-B4C7-838E6D2102E7Q26471538-7A1CFB93-5002-477F-BAE9-B305C4A658E8Q26786229-AC3632D1-FA07-47F9-8E0F-243414169272Q26824970-11DCD87A-BAD3-4D70-A0CB-31AD9D61E901Q27014877-09A9C3B5-5238-42A6-8340-149D56D0074BQ30957102-4AC73254-5EA1-4A8C-8B55-14114557EBC7Q33591510-0874458A-30FF-4E34-BF36-11406EC7ABEFQ33628563-34A97E60-414D-4F8B-8E0B-1C52B0D4C8F1Q33809045-6DA6439E-83D1-46AB-B7EC-4F3A3EE5814CQ35056149-E0E65386-905B-452D-9FDB-0F3DA7C46F22Q35618458-6B818365-4FD7-403A-A3CC-48AA0FBA9E7EQ35897669-9D82D6C2-F503-4403-BA4A-D6A60353F850Q36072925-9AB77473-D7A8-49F3-9C29-2E952A9EC758Q36943002-8629FC99-0383-4104-866A-78A6BFA21290Q37250988-F66EBFA9-B936-4971-A240-F46E8B9BE5CCQ38131512-C10E2711-6D98-4830-8597-BE8B00DA19CCQ38164315-CBFA5AF8-C515-4C81-8154-4491D6FD0E75Q38182440-E5CE7713-9E7E-4E22-B7C3-97B8CC55E610Q38237564-F21D553D-5775-47E0-934C-F972400BAEEDQ38871034-FEBC95B5-2783-4FFF-BD0D-4ACCBBADA5BBQ38939820-90A1A866-4E8A-45BE-8CEB-80030C5EB28AQ39230189-6914D90E-0E6F-4AF5-BE2D-C9DD909152FBQ40235629-8E872B06-38FE-4B84-9E71-9FA984986826Q41687126-84B584D8-BD99-4E31-9CFC-AABE3FB01ED3Q44818742-37ADD4EC-3A7C-4CC3-B9E2-5FE11DA8F80BQ47549539-EFC6D8EB-B403-43D3-9115-68F452F5169DQ47886068-C539FA08-AAE5-4E78-A772-C59FFED2032CQ48542399-2DDE9DCB-4266-4DC4-BAC2-F9D7D6C13E54Q52675492-C34F1D8C-C53A-4416-8C97-6173D2191855Q53789625-9C67A632-EBBC-4285-9362-A0CA139034F3Q55058284-D72DBA3E-14CC-4864-8BFD-2D8070B5115DQ55396986-BCA7BEC7-6BB2-4C98-BA10-59B6DC8B35D0
P2860
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Improvements in health-related ...... mized controlled RADIATE study
@ast
Improvements in health-related ...... mized controlled RADIATE study
@en
Improvements in health-related ...... mized controlled RADIATE study
@en-gb
type
label
Improvements in health-related ...... mized controlled RADIATE study
@ast
Improvements in health-related ...... mized controlled RADIATE study
@en
Improvements in health-related ...... mized controlled RADIATE study
@en-gb
prefLabel
Improvements in health-related ...... mized controlled RADIATE study
@ast
Improvements in health-related ...... mized controlled RADIATE study
@en
Improvements in health-related ...... mized controlled RADIATE study
@en-gb
P2093
P2860
P921
P356
P1433
P1476
Improvements in health-related ...... mized controlled RADIATE study
@en
P2093
Jenny Devenport
Sarika Ogale
Vibeke Strand
P2860
P304
P356
10.1093/RHEUMATOLOGY/KES131
P577
2012-06-28T00:00:00Z
P5875
P6179
1040128506